Why the study?
Does antihypertensive therapy reduce cardiovascular endpoints and microvascular disease in people with diabetes?
Does antihypertensive therapy reduce cardiovascular endpoints and microvascular disease in people with diabetes?
Blood pressure lowering in diabetic subjects reduces cardiovascular and microvascular disease, highlighting the need for tight blood pressure targets (<= 140/80) often requiring combination therapy.
May support BP lowering in diabetes; leaves open optimal targets and regimens pending higher-level evidence.
Hypertension is common in people with diabetes with an estimated prevalence using the new criteria (> or = 140/90) at 70%. The recent large randomized controlled studies in diabetic subjects has clearly shown the benefit of blood pressure lowering with reduction in cardiovascular endpoints and microvascular disease. ACE inhibitors, calcium antagonists, thiazide diuretics and beta-blocking agents have been the agents validated by the trials. The challenge now is to implement antihypertensive therapy to achieve tight blood pressure targets (< or = 140/80), usually requiring dual or even triple therapeutic regimens.
No takes yet. Share an insight, caveat, or question.
P M Dodson (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: